Shiitake mushroom,
does it really help with Immunity, anticancer?
research showsShiitake mushroom and lentinan have small human studies looking at immune-cell markers and Japanese studies of cancer adjunctive therapy. However, lentinan anticancer signals are in the context of adjunctive therapy combined with chemotherapy for specific cancers and injectable/drug formulations; oral shiitake supplements do not automatically inherit that evidence.
ads claimAdvertising mentions 'immunity,' 'NK cells,' 'anticancer mushroom,' 'beta-glucan,' and 'cancer prevention.' Clinical evidence concerns immune surrogate markers or adjunctive therapy in specific medical contexts, not general prevention.
Useful facts when choosing a product
- Studies of lentinan injections/drugs are not the same as food shiitake mushroom extracts.
- Dried shiitake, AHCC, lentinan, and beta-glucan combination products are different raw materials.
- General oral supplement anticancer and cancer-prevention claims should be separated from evidence for lentinan adjunctive therapy.
- Adverse reactions such as shiitake dermatitis, allergy, and eosinophilia have been reported.
- During cancer treatment, supplement use and possible interactions with anticancer therapy should be checked with clinicians.
What the research actually shows
A 2015 JACN study reported proliferation of γδ-T cells and NK-T cells and changes in inflammatory markers after 52 healthy adults consumed dried shiitake mushroom 5 g or 10 g/day for 4 weeks. These are immune surrogate markers, not clinical endpoints such as fewer infections. The Oba 2009 individual patient data meta-analysis reported survival-related signals when lentinan was combined in unresectable/recurrent gastric cancer, but there are major limitations because this is adjunctive therapy combined with anticancer treatment, a specific cancer type, and an injectable/drug context. Oral superfine dispersed lentinan studies are often small, nonrandomized, or open-label, so they are difficult to transfer directly to anticancer evidence for ordinary oral supplements sold in the United States and elsewhere.
Why this is classified as C (41)
Because human studies exist, this is not unknown or D, but for health-functional-food immunity and anticancer claims, the evidence remains at NK/cytokine surrogate markers and adjunctive-therapy evidence for specific cancers. Anticancer signals are in chemotherapy-combination and injectable/drug contexts, so they are not generalized to anticancer/cancer-prevention effects of general supplements, and this is kept at C, 41 points.
Counterpoint. Lentinan combination-therapy studies are not evidence to ignore completely, but there is a large gap when converting them to efficacy claims for general consumer oral shiitake supplements.
Rejudgment record. Final — Immunity evidence centers on NK/cytokine surrogate markers, and lentinan anticancer signals are in chemotherapy-combination adjunctive therapy and injectable/drug contexts for specific cancers, so they are separated from general supplement anticancer/cancer-prevention claims
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Dai X et al. 2015 | Randomized dietary-intervention study | 52 | Academic/possible agricultural support | Immune-cell and cytokine surrogate markers | Changes in γδ-T cells, NK-T cells, and inflammatory markers were reported after dried shiitake intake. | Supporting |
| Oba K et al. 2009 | Individual patient data meta-analysis | Japanese lentinan research group/unknown | Survival | Reported survival signals in specific gastric-cancer contexts when lentinan was added to chemotherapy. | Supporting | |
| Hazama S et al. 2009 | Small clinical study | Unknown/possible product involvement | Quality of life, immune markers, adjunctive treatment | Reported adjunctive oral superfine dispersed lentinan signals, but the design limitations were large. | Supporting |
Receipt — 4 References
Every cited source was opened and checked against the live page on 2026-07-09.
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none
Cite this verdict
[Chamgap] Shiitake mushroom (lentinan) × immunity, anticancer — Evidence Grade C·41. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/immunity/shiitake-lentinan-immune-cancer/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.